IPO, page-52

One thing that I'm hopeful for PGA is that the IPO will raise funds to push the AMD and Hep B programs faster. That would be the flip side in the Tribetarna delay. With those two programs moving forward sooner, it could offset the lack of progress in the Tribetarna delay. That's my hope, at least. The last presentation showed some significant progress in the AMD transduction, and given the recent AMD failure with other companies, this could be a program that we also can monopolize on.
I'm no fan of the possible cons, but pushing these programs with IPO funds may very well be the injection of cash and Nasdaq exposure we need to push this company out into the spotlight...as well as being in a market that appreciates biotech companies.